1Piovella F, Wang CJ, Lu H, et al. Deep-vein thrombosis ratesaftermajor orthopedic surgery in Asia. An ep idemiological studybased on postoperative screening with centrally adjudicatedbilateral venography [ J]. J Thromb Haemost, 2005,3 : 2664 -2670.
2Geerts WH, Bergqvist D, Pineo GF, et al. Prevention of venousthromboembolism. American College of Chest Physicians evidence-based clinical practice guidelines ( 8th edn) [ J]. Chest, 2008 ,133: 381S-453S.
3Donald JP, Michael JO, Stephanie K, et al. Discovery of 1-(4-Methoxyphenyl) -7-oxo-6-(4-( 2-oxopiperidin-l -yl) phenyl) A,5,6,7-tetrahydro-l H-pyrazolo [ 3, 4-c ] pyridine-3 -carboxamide(apixaban, BMS-562247 ),a highly potent, selective,efficacious, and orally bioavmlable inhibitor of blood coagulationfactor Xa [ J ]. J Med Chem, 2007,50: 5339 -5356.
7Charles F, Sunil N, Jessie Wang, et al. Safety, pharmaco- kinetics and pharmaeodynamics of multiple oral doses of apixaban, a factor X a inhibitor, in healthy subjects[J]. British Journal of Clinical Pharmacology, 2013,76 (5) : 776.
9MARTIN A,STEWART R. Safety and efficacy of apixaban in the treatment of atrial fibrillation [ J ~. Clinmed Insights Cardiol, 2012,6 ( 1 ) : 103 - 109.
